STOCK TITAN

Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
Krystal Biotech, Inc. (KRYS) will release its Q4 and full year 2023 financial results on February 26, 2024, followed by a webcast for financial updates. An investor webcast will also be held on the same day at 8:30 am ET.
Positive
  • None.
Negative
  • None.

PITTSBURGH, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, will report its fourth quarter and full year 2023 financial results on Monday, February 26, 2024, prior to the open of U.S. markets. Subsequently, at 8:30 am ET, the Company will host a webcast to discuss the financial results and provide a business update.

Investor Conference Call

The Company will host an investor webcast on Monday, February 26, 2024 at 8:30 am ET.

Investors and the general public can access the live webcast at https://www.webcaster4.com/Webcast/Page/3018/49928.

For those unable to listen to the live webcast, a replay will be available for 30-days on the Investors section of the Company’s website at www.krystalbio.com.

About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK® is the Company’s first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).

CONTACT
Investors and Media:                                                             
Meg Dodge                                                      
Krystal Biotech                                                    
mdodge@krystalbio.com                                  


Krystal Biotech will report its Q4 and full year 2023 financial results on Monday, February 26, 2024.

The webcast for financial updates will be held at 8:30 am ET on February 26, 2024.

Investors and the general public can access the live webcast at https://www.webcaster4.com/Webcast/Page/3018/49928.

A replay of the webcast will be available for 30 days on the Investors section of the Company's website at www.krystalbio.com.
Krystal Biotech Inc

NASDAQ:KRYS

KRYS Rankings

KRYS Latest News

KRYS Stock Data

Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Health Technology, Pharmaceuticals: Major, Manufacturing, Biological Product (except Diagnostic) Manufacturing
US
Pittsburgh

About KRYS

krystal biotech, inc. is using gene therapy to develop effective and novel treatments for skin diseases. our goal is to make a meaningful difference in the lives of underserved patient populations with debilitating skin diseases. we work to accomplish that through scientific innovation, operational excellence and believe that “nature operates in the shortest way possible”. (aristotle)